. 2023 Apr 5;24:89. doi: 10.1186/s12882-023-03145-x

Table 3.

Inclusion and exclusion criteria for the KBindER study

Inclusion Criteria	Exclusion Criteria
▪ Plasma K⁺ ≥ 5.5 mEq/L ▪ Age ≥ 18 years ▪ English or Spanish speaking ▪ Patient able to provide written informed consent	▪ Recent Bowel Surgery ▪ Ileus or bowel obstruction ▪ Received a dose of an oral potassium binder in past 48 h ▪ Hemolyzed blood specimen as indicated by the laboratory ▪ Severe leukocytosis or thrombocytosis ▪ Pregnancy ▪ Active psychiatric disorder ▪ Diabetic ketoacidosis or hyperkalemia caused by any condition for which a therapy directed against the underlying cause is expected to correct the hyperkalemia ▪ Dialysis session expected within 4 h after randomization ▪ History or hypersensitivity to any of the study drugs ▪ Concurrent use of sorbitol (due to increased risk of intestinal necrosis when used with SPS)

Inclusion Criteria

Exclusion Criteria

▪ Plasma K⁺ ≥ 5.5 mEq/L

▪ Age ≥ 18 years

▪ English or Spanish speaking

▪ Patient able to provide written informed consent

▪ Recent Bowel Surgery

▪ Ileus or bowel obstruction

▪ Received a dose of an oral potassium binder in past 48 h

▪ Hemolyzed blood specimen as indicated by the laboratory

▪ Severe leukocytosis or thrombocytosis

▪ Pregnancy

▪ Active psychiatric disorder

▪ Diabetic ketoacidosis or hyperkalemia caused by any condition for which a therapy directed against the underlying cause is expected to correct the hyperkalemia

▪ Dialysis session expected within 4 h after randomization

▪ History or hypersensitivity to any of the study drugs

▪ Concurrent use of sorbitol (due to increased risk of intestinal necrosis when used with SPS)